BioSpace News Archive

Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Denice Torres will join the company’s board of directors.

LogicBio Therapeutics, Inc. today announced that Frederic Chereau , chief executive officer of LogicBio, will participate in a virtual panel discussion entitled “Delivery and Durability of Genetic Medicines” at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET.

Aeglea BioTherapeutics, Inc. today announced the appointment of Jonathan D. Alspaugh as Chief Financial Officer.

Checkpoint Therapeutics, Inc. today announced that James Oliviero, President and Chief Executive Officer, will participate in the Ladenburg Thalmann 2021 Healthcare Conference, taking place July 13-14, 2021.

Applied Biosystems RapidHIT ID DNA Booking System enables seamless integration of Rapid DNA into the law enforcement booking agency process

ONWARD announced Andy Dolan, a marketing executive with 20 years’ health sector experience, has joined the company as Vice President of Marketing.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announces updated results and safety measures based on the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melphalan flufenamide plus dexamethasone versus pomalidomide plus dexamethasone in patients with relapsed refractory multiple myeloma who have received 2 - 4 prior lines of therapy.

The constipation treatment market is expected to reach US$ 13,386.19 million in 2027 from US$ 8,533.89 million in 2019. The market is estimated to grow with a CAGR of 5.9% from 2020-2027.

According to The Insight Partners market research study titled ‘Insulin Delivery Devices Market to 2025 - Global Analysis and Forecasts by Product and End User, the global insulin delivery devices market was valued at US$ 11,869.0 Mn in 2017 and is estimated to reach US$ 22,830.0 Mn by 2025.

For the first half of 2021, Median Technologies’ revenue amounts to €10.1m, up 71% compared to the H1 2020 revenue, which stood at €5.9m.